Sign Out
Metabolism/Transport Effects: None known. Avoid Concomitant Use: Avoid concomitant use of Insulin Glargine with any of the following: Macimorelin; Pioglitazone.
Increased Effect/Toxicity: Insulin Glargine may increase the levels/effects of Hypoglycemia-Associated Agents: Pioglitazone.
The levels/effects of Insulin Glargine may be increased by: Alpha-Lipoic Acid; Androgens; Antidiabetic Agents; Beta-Blockers; Dipeptidyl Peptidase-IV Inhibitors; Edetate Calcium Disodium; Edetate Disodium; Glucagon-Like Peptide-1 Agonists; Guanethidine; Herbs (Hypoglycemic Properties); Liraglutide; Metreleptin; Monoamine Oxidase Inhibitors; Pegvisomant; Pioglitazone; Pramlintide; Prothionamide; Quinolones; Salicylates; Selective Serotonin Reuptake Inhibitors; Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors.
Decreased Effect: Insulin Glargine may decrease the levels/effects of: Macimorelin.
The levels/effects of Insulin Glargine may be decreased by: Hyperglycemia-Associated Agents: Quinolones; Ritodrine; Thiazide and Thiazide-Like Diuretics.
